TD Cowen analyst Shaul Eyal raised the firm’s price target on Cellebrite (CLBT) to $30 from $25 and keeps a Buy rating on the shares. The firm updated its model following solid, consensus beating Q4 results. Cowen said healthy demand and strong execution are enabling Rule-of-50 performance.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLBT:
- Cellebrite Reports Strong Growth in 2024 Earnings
- Strategic Initiatives and Long-term Growth Drive Buy Rating for Cellebrite DI
- Cellebrite Achieves Strong 2024 Financial Performance with Significant ARR Growth
- Cellebrite reports Q4 EPS 10c, consensus 10c
- Cellebrite sees Q1 revenue $107M-$112M, consensus $105.54M